Which has preferable earnings & valuation, ECOR or ELMD?

Electromed has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio electroCore $32.03M 2.68 -$13.97M -$1.66 N/A Electromed $73.78M 3.20 $5.15M $1.31 21.56

Is ECOR or ELMD more profitable?

Electromed has a net margin of 11.34% compared to electroCore's net margin of -39.96%. Electromed's return on equity of 15.71% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets electroCore -39.96% -1,956.38% -81.35% Electromed 11.34% 15.71% 13.37%

Is ECOR or RCEL more profitable?

electroCore has a net margin of -39.96% compared to Avita Medical's net margin of -56.96%. Avita Medical's return on equity of 0.00% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets electroCore -39.96% -1,956.38% -81.35% Avita Medical -56.96% N/A -78.53%

Which has stronger earnings & valuation, CV or ECOR?

electroCore has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.55M 21.90 -$25.32M -$0.47 N/A electroCore $32.03M 2.68 -$13.97M -$1.66 N/A

Is CV or ECOR more profitable?

electroCore has a net margin of -39.96% compared to CapsoVision's net margin of -214.74%. CapsoVision's return on equity of -177.85% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -214.74% -177.85% -135.07% electroCore -39.96% -1,956.38% -81.35%

electroCore (ECOR) Competitors

$9.51 +0.46 (+5.08%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$9.68 +0.17 (+1.79%)

As of 04:09 AM Eastern

Compare

ECOR vs. OBIO, ELMD, TLSI, RCEL, and CV

Should you buy electroCore stock or one of its competitors? electroCore's main competitors and comparable companies include Orchestra BioMed (OBIO), Electromed (ELMD), TriSalus Life Sciences (TLSI), Avita Medical (RCEL), and CapsoVision (CV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does electroCore compare to Orchestra BioMed?

electroCore (NASDAQ:ECOR) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

electroCore has a net margin of -39.96% compared to Orchestra BioMed's net margin of -184.60%. Orchestra BioMed's return on equity of -149.61% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-39.96%	-1,956.38%	-81.35%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

electroCore has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Orchestra BioMed has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

26.7% of electroCore shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 7.8% of electroCore shares are held by insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

electroCore has higher earnings, but lower revenue than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	2.68	-$13.97M	-$1.66	N/A
Orchestra BioMed	$33.48M	8.89	-$52.70M	-$0.85	N/A

In the previous week, Orchestra BioMed had 7 more articles in the media than electroCore. MarketBeat recorded 7 mentions for Orchestra BioMed and 0 mentions for electroCore. electroCore's average media sentiment score of 1.84 beat Orchestra BioMed's score of 1.19 indicating that electroCore is being referred to more favorably in the media.

Company	Overall Sentiment
electroCore	Very Positive
Orchestra BioMed	Positive

electroCore currently has a consensus price target of $18.00, indicating a potential upside of 89.27%. Orchestra BioMed has a consensus price target of $13.00, indicating a potential upside of 162.63%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Orchestra BioMed beats electroCore on 10 of the 16 factors compared between the two stocks.

How does electroCore compare to Electromed?

electroCore (NASDAQ:ECOR) and Electromed (NYSE:ELMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Electromed had 2 more articles in the media than electroCore. MarketBeat recorded 2 mentions for Electromed and 0 mentions for electroCore. electroCore's average media sentiment score of 1.84 beat Electromed's score of 0.55 indicating that electroCore is being referred to more favorably in the media.

Company	Overall Sentiment
electroCore	Very Positive
Electromed	Positive

electroCore has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Electromed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

electroCore presently has a consensus price target of $18.00, suggesting a potential upside of 89.27%. Electromed has a consensus price target of $43.75, suggesting a potential upside of 54.92%. Given electroCore's higher possible upside, analysts plainly believe electroCore is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Electromed has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	2.68	-$13.97M	-$1.66	N/A
Electromed	$73.78M	3.20	$5.15M	$1.31	21.56

Electromed has a net margin of 11.34% compared to electroCore's net margin of -39.96%. Electromed's return on equity of 15.71% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-39.96%	-1,956.38%	-81.35%
Electromed	11.34%	15.71%	13.37%

26.7% of electroCore shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 7.8% of electroCore shares are held by company insiders. Comparatively, 10.5% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Electromed beats electroCore on 13 of the 16 factors compared between the two stocks.

How does electroCore compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and electroCore (NASDAQ:ECOR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by insiders. Comparatively, 7.8% of electroCore shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TriSalus Life Sciences currently has a consensus target price of $7.50, indicating a potential upside of 45.91%. electroCore has a consensus target price of $18.00, indicating a potential upside of 89.27%. Given electroCore's higher probable upside, analysts plainly believe electroCore is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

electroCore has a net margin of -39.96% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
electroCore	-39.96%	-1,956.38%	-81.35%

electroCore has lower revenue, but higher earnings than TriSalus Life Sciences. electroCore is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.08M	7.02	-$39.23M	-$1.30	N/A
electroCore	$32.03M	2.68	-$13.97M	-$1.66	N/A

TriSalus Life Sciences has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, electroCore has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

In the previous week, TriSalus Life Sciences had 2 more articles in the media than electroCore. MarketBeat recorded 2 mentions for TriSalus Life Sciences and 0 mentions for electroCore. electroCore's average media sentiment score of 1.84 beat TriSalus Life Sciences' score of 0.77 indicating that electroCore is being referred to more favorably in the news media.

Company	Overall Sentiment
TriSalus Life Sciences	Positive
electroCore	Very Positive

Summary

TriSalus Life Sciences beats electroCore on 10 of the 16 factors compared between the two stocks.

How does electroCore compare to Avita Medical?

electroCore (NASDAQ:ECOR) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

electroCore presently has a consensus price target of $18.00, indicating a potential upside of 89.27%. Avita Medical has a consensus price target of $11.40, indicating a potential upside of 5.95%. Given electroCore's higher probable upside, equities research analysts clearly believe electroCore is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

26.7% of electroCore shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 7.8% of electroCore shares are held by insiders. Comparatively, 2.2% of Avita Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

electroCore has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Avita Medical has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market.

electroCore has higher earnings, but lower revenue than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	2.68	-$13.97M	-$1.66	N/A
Avita Medical	$71.61M	4.62	-$48.59M	-$1.44	N/A

In the previous week, Avita Medical had 1 more articles in the media than electroCore. MarketBeat recorded 1 mentions for Avita Medical and 0 mentions for electroCore. electroCore's average media sentiment score of 1.84 beat Avita Medical's score of 1.00 indicating that electroCore is being referred to more favorably in the media.

Company	Overall Sentiment
electroCore	Very Positive
Avita Medical	Positive

electroCore has a net margin of -39.96% compared to Avita Medical's net margin of -56.96%. Avita Medical's return on equity of 0.00% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-39.96%	-1,956.38%	-81.35%
Avita Medical	-56.96%	N/A	-78.53%

Summary

Avita Medical beats electroCore on 10 of the 16 factors compared between the two stocks.

How does electroCore compare to CapsoVision?

CapsoVision (NASDAQ:CV) and electroCore (NASDAQ:ECOR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

electroCore has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	21.90	-$25.32M	-$0.47	N/A
electroCore	$32.03M	2.68	-$13.97M	-$1.66	N/A

electroCore has a net margin of -39.96% compared to CapsoVision's net margin of -214.74%. CapsoVision's return on equity of -177.85% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
electroCore	-39.96%	-1,956.38%	-81.35%

26.7% of electroCore shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 7.8% of electroCore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CapsoVision has a beta of -2.47, suggesting that its stock price is 347% less volatile than the broader market. Comparatively, electroCore has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

CapsoVision presently has a consensus target price of $9.50, suggesting a potential upside of 60.20%. electroCore has a consensus target price of $18.00, suggesting a potential upside of 89.27%. Given electroCore's higher probable upside, analysts plainly believe electroCore is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, CapsoVision had 5 more articles in the media than electroCore. MarketBeat recorded 5 mentions for CapsoVision and 0 mentions for electroCore. electroCore's average media sentiment score of 1.84 beat CapsoVision's score of 0.60 indicating that electroCore is being referred to more favorably in the news media.

Company	Overall Sentiment
CapsoVision	Positive
electroCore	Very Positive

Summary

electroCore beats CapsoVision on 10 of the 16 factors compared between the two stocks.

Get electroCore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ECOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ECOR vs. The Competition

Export

Metric	electroCore	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$81.59M	$5.75B	$7.21B	$12.67B
Dividend Yield	N/A	1.75%	2.53%	8.56%
P/E Ratio	-5.73	25.86	272.66	25.23
Price / Sales	2.68	80.80	635.76	104.55
Price / Cash	N/A	33.05	76.98	52.08
Price / Book	-30.68	6.08	12.83	6.10
Net Income	-$13.97M	$147.75M	$3.47B	$348.86M
7 Day Performance	-2.06%	-0.74%	-0.12%	-1.90%
1 Month Performance	56.16%	3.77%	6.74%	1.96%
1 Year Performance	86.11%	7.38%	25.09%	15.30%

electroCore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ECOR electroCore	3.4833 of 5 stars	$9.51 +5.1%	$18.00 +89.3%	+80.8%	$81.59M	$32.03M	N/A	50	Positive News
OBIO Orchestra BioMed	3.275 of 5 stars	$5.36 -1.5%	$13.00 +142.5%	+80.7%	$326.97M	$33.48M	N/A	4	Positive News
ELMD Electromed	2.9636 of 5 stars	$39.34 -2.4%	$37.50 -4.7%	+17.9%	$325.74M	$71.75M	52.45	160	News Coverage Positive News
TLSI TriSalus Life Sciences	1.2301 of 5 stars	$5.03 -1.6%	$7.50 +49.1%	-0.4%	$314.65M	$45.15M	N/A	106
RCEL Avita Medical	2.4838 of 5 stars	$10.50 +6.0%	$10.20 -2.9%	+150.8%	$305M	$71.61M	N/A	130	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ECOR) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

electroCore (ECOR) Competitors

ECOR vs. OBIO, ELMD, TLSI, RCEL, and CV

How does electroCore compare to Orchestra BioMed?

Summary

How does electroCore compare to Electromed?

Summary

How does electroCore compare to TriSalus Life Sciences?

Summary

How does electroCore compare to Avita Medical?

Summary

How does electroCore compare to CapsoVision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ECOR vs. The Competition

electroCore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

electroCore (ECOR) Competitors

ECOR vs. OBIO, ELMD, TLSI, RCEL, and CV

How does electroCore compare to Orchestra BioMed?

Is ECOR or OBIO more profitable?

Which has more risk & volatility, ECOR or OBIO?

Do insiders and institutionals believe in ECOR or OBIO?

Which has higher valuation & earnings, ECOR or OBIO?

Does the media prefer ECOR or OBIO?

Do analysts prefer ECOR or OBIO?

Summary

How does electroCore compare to Electromed?

Does the media refer more to ECOR or ELMD?

Which has more volatility and risk, ECOR or ELMD?

Do analysts recommend ECOR or ELMD?

Which has preferable earnings & valuation, ECOR or ELMD?

Is ECOR or ELMD more profitable?

Do insiders & institutionals have more ownership in ECOR or ELMD?

Summary

How does electroCore compare to TriSalus Life Sciences?

Do institutionals & insiders believe in TLSI or ECOR?

Do analysts prefer TLSI or ECOR?

Is TLSI or ECOR more profitable?

Which has higher earnings & valuation, TLSI or ECOR?

Which has more volatility & risk, TLSI or ECOR?

Does the media favor TLSI or ECOR?

Summary

How does electroCore compare to Avita Medical?

Do analysts rate ECOR or RCEL?

Do institutionals & insiders believe in ECOR or RCEL?

Which has more volatility & risk, ECOR or RCEL?

Which has better earnings & valuation, ECOR or RCEL?

Does the media refer more to ECOR or RCEL?

Is ECOR or RCEL more profitable?

Summary

How does electroCore compare to CapsoVision?

Which has stronger earnings & valuation, CV or ECOR?

Is CV or ECOR more profitable?

Do insiders & institutionals hold more shares of CV or ECOR?

Which has more volatility & risk, CV or ECOR?

Do analysts rate CV or ECOR?

Does the media prefer CV or ECOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ECOR vs. The Competition

electroCore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools